Introduction Refractory and super-refractory status epilepticus are medical emergencies that must be promptly treated in consideration of their high mortality and morbidity rate. Nevertheless, the available evidence of effective treatment of these conditions is scarce. Among novel antiseizure medications (ASMs), highly purified cannabidiol (hpCBD) has shown noteworthy efficacy in reducing seizures in Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), and Tuberous Sclerosis Complex (TSC).Case Presentation Here, we present two cases of effective use of hpCBD in both refractory and super-refractory status epilepticus. The administration of the nasogastric tube permitted the resolution of status epilepticus without adverse events. At 6-month follow-up, both patients were on hpCBD treatment, which continued to be efficacious for treating seizures.Conclusion According to our experience, hpCBD should be taken into consideration as an add-on therapy of RSE and SRSE while also considering the possibility of maintaining this treatment during the follow-up of patients. However, more studies and real-world experiences are needed to better understand its effectiveness in this setting and the interaction with other ASMs.

Di Mauro, G., Vietri, G., Quaranta, L., Placidi, F., Izzi, F., Castelli, A., et al. (2025). Effectiveness of Highly Purified Cannabidiol in Refractory and Super-Refractory Status Epilepticus: A Case Series. CNS & NEUROLOGICAL DISORDERS. DRUG TARGETS, 24(2), 158-163 [10.2174/0118715273304077240603115521].

Effectiveness of Highly Purified Cannabidiol in Refractory and Super-Refractory Status Epilepticus: A Case Series

Di Mauro G.;Vietri G.;Placidi F.;Izzi F.;Leonardis F.;Bianco C.;Mercuri N. B.;Liguori C.
2025-01-01

Abstract

Introduction Refractory and super-refractory status epilepticus are medical emergencies that must be promptly treated in consideration of their high mortality and morbidity rate. Nevertheless, the available evidence of effective treatment of these conditions is scarce. Among novel antiseizure medications (ASMs), highly purified cannabidiol (hpCBD) has shown noteworthy efficacy in reducing seizures in Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), and Tuberous Sclerosis Complex (TSC).Case Presentation Here, we present two cases of effective use of hpCBD in both refractory and super-refractory status epilepticus. The administration of the nasogastric tube permitted the resolution of status epilepticus without adverse events. At 6-month follow-up, both patients were on hpCBD treatment, which continued to be efficacious for treating seizures.Conclusion According to our experience, hpCBD should be taken into consideration as an add-on therapy of RSE and SRSE while also considering the possibility of maintaining this treatment during the follow-up of patients. However, more studies and real-world experiences are needed to better understand its effectiveness in this setting and the interaction with other ASMs.
2025
Pubblicato
Rilevanza internazionale
Articolo
Esperti non anonimi
Settore MEDS-12/A - Neurologia
Settore MEDS-23/A - Anestesiologia
English
Status epilepticus
anti-seizure medication
emergency
epilepsy
lennox-gastaut syndrome
seizure
Di Mauro, G., Vietri, G., Quaranta, L., Placidi, F., Izzi, F., Castelli, A., et al. (2025). Effectiveness of Highly Purified Cannabidiol in Refractory and Super-Refractory Status Epilepticus: A Case Series. CNS & NEUROLOGICAL DISORDERS. DRUG TARGETS, 24(2), 158-163 [10.2174/0118715273304077240603115521].
Di Mauro, G; Vietri, G; Quaranta, L; Placidi, F; Izzi, F; Castelli, A; Pagano, A; Leonardis, F; De Angelis, V; Bianco, C; Celeste, Mg; Mercuri, Nb; Li...espandi
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/434483
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 1
social impact